Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Intrahepatic Cholangiocarcinoma Market to Grow Rapidly During the Study Period (2019-2032), Examines DelveInsight | Key Players - Virogin Biotech, Syndax, Delcath Systems, AstraZeneca, Amgen, Jazz, BeiGene

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

20 Sep, 2023, 21:01 GMT

Share this article

Share toX

Share this article

Share toX

The dynamics of the intrahepatic cholangiocarcinoma market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending worldwide, and the expected launch of emerging therapies

LAS VEGAS, Sept. 20, 2023 /PRNewswire/ -- DelveInsight's Intrahepatic Cholangiocarcinoma Market Insights report includes a comprehensive understanding of current treatment practices, intrahepatic cholangiocarcinoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Intrahepatic Cholangiocarcinoma Market Report

  • As per DelveInsight analysis, the intrahepatic cholangiocarcinoma market is expected to grow positively at a significant CAGR during the study period (2019–2032).
  • In the Western world, the incidence of intrahepatic cholangiocarcinoma is 1 to 2 per 100,000. Intrahepatic cholangiocarcinoma is the second most prevalent liver cancer, accounting for 3% of all gastrointestinal cancer cases. 
  • Leading intrahepatic cholangiocarcinoma companies such as Virogin Biotech Ltd., Syndax Pharmaceuticals, Delcath Systems Inc., TriSalus Life Sciences, Inc., AstraZeneca, Relay Therapeutics, Inc., Kinnate Biopharma, Elucida Oncology, Lisata Therapeutics, Inc., Amgen, Jazz Pharmaceuticals, BeiGene, Ltd., and others are developing novel intrahepatic cholangiocarcinoma drugs that can be available in the intrahepatic cholangiocarcinoma market in the coming years.
  • Some key therapies for intrahepatic cholangiocarcinoma treatment include VG161, SNDX-6352, Cisplatin and Gemcitabine, SD-101, Y-90 With Durvalumab/Gem/Cis, RLY-4008, KIN-3248, ELU001, LSTA1, Bemarituzumab, ZW25 (Zanidatamab), and others.

Discover which therapies are expected to grab the major intrahepatic cholangiocarcinoma market share @ Intrahepatic Cholangiocarcinoma Market Report

Intrahepatic Cholangiocarcinoma Overview

Intrahepatic cholangiocarcinoma, a rare and aggressive form of cancer, originates in the bile ducts within the liver. While the exact causes are not always clear, certain risk factors have been identified. Chronic inflammation of the bile ducts, often due to conditions like primary sclerosing cholangitis or chronic liver infections, can increase the risk. Additionally, exposure to certain chemicals and toxins may play a role in the development of this cancer. Symptoms of intrahepatic cholangiocarcinoma can be subtle and nonspecific, which makes early diagnosis challenging. Common symptoms include jaundice, abdominal pain, unexplained weight loss, and fatigue. Some patients may also experience itching, dark urine, or pale-colored stools. Diagnosing intrahepatic cholangiocarcinoma typically involves a combination of imaging tests, such as CT scans, MRI scans, and ultrasound, to visualize the tumor within the liver. A biopsy may be necessary to confirm the diagnosis, where a small sample of tissue is extracted and examined under a microscope.

Intrahepatic Cholangiocarcinoma Epidemiology Segmentation

The intrahepatic cholangiocarcinoma epidemiology section provides insights into the historical and current intrahepatic cholangiocarcinoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. 

The disease epidemiology covered in the report provides historical as well as forecasted intrahepatic cholangiocarcinoma epidemiology scenarios in the 7MM covering the United States, EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan from 2019 to 2032.

Intrahepatic Cholangiocarcinoma Treatment Market 

Treatment for intrahepatic cholangiocarcinoma depends on several factors, including the stage of the cancer, the patient's overall health, and individual preferences. Typically, intrahepatic cholangiocarcinoma treatment options include surgery, liver transplantation, chemotherapy, radiation therapy, and targeted therapies. Surgery, such as a partial hepatectomy, is often the preferred treatment when the cancer is detected early and is localized to a specific area of the liver. Liver transplantation may be an option for some patients with advanced intrahepatic cholangiocarcinoma. Chemotherapy, often in combination with targeted therapies, is used to shrink tumors before surgery or to treat cancer that has spread beyond the liver. Radiation therapy may also be employed to target and destroy cancer cells. Additionally, advancements in immunotherapy and clinical trials offer hope for novel treatment avenues. The intrahepatic cholangiocarcinoma treatment necessitates a personalized approach, with healthcare teams comprising oncologists, surgeons, radiologists, and other specialists collaborating closely to determine the most effective strategy for each patient. Early diagnosis and timely intervention remain pivotal in improving prognosis and overall outcomes for individuals with this challenging form of liver cancer.

To know more about intrahepatic cholangiocarcinoma treatment, visit @ Intrahepatic Cholangiocarcinoma Treatment Drugs 

Key Intrahepatic Cholangiocarcinoma Therapies and Companies

  • VG161: Virogin Biotech Ltd.
  • SNDX-6352: Syndax Pharmaceuticals
  • Cisplatin and Gemcitabine: Delcath Systems Inc.
  • SD-101: TriSalus Life Sciences, Inc.
  • Y-90 With Durvalumab/Gem/Cis: AstraZeneca
  •  RLY-4008: Relay Therapeutics, Inc.
  • KIN-3248: Kinnate Biopharma
  • ELU001: Elucida Oncology
  • LSTA1: Lisata Therapeutics, Inc.
  • Bemarituzumab: Amgen
  • ZW25 (Zanidatamab): Jazz Pharmaceuticals/BeiGene, Ltd.

Learn more about the FDA-approved drugs for intrahepatic cholangiocarcinoma @ Drugs for Intrahepatic Cholangiocarcinoma Treatment 

Intrahepatic Cholangiocarcinoma Market Dynamics

The intrahepatic cholangiocarcinoma market dynamics have been undergoing significant changes in recent years. The growing awareness and improved diagnostic techniques have led to an earlier detection of ICC cases. This, coupled with advancements in treatment modalities such as surgical resection, liver transplantation, and targeted therapies, has expanded the range of therapeutic options available to patients. Additionally, ongoing research into immunotherapies and intrahepatic cholangiocarcinoma is providing new hope for more effective treatments. As a result, the intrahepatic cholangiocarcinoma market is witnessing increased investments in research and development, heightened competition among pharmaceutical companies, and a focus on developing innovative therapies tailored to the specific molecular characteristics of individual patients. These evolving dynamics are poised to transform the landscape of intrahepatic cholangiocarcinoma treatment, offering improved prospects for patients facing this challenging disease.

Intrahepatic cholangiocarcinoma faces several notable barriers within its market dynamics. Firstly, the rarity of intrahepatic cholangiocarcinoma makes it challenging to conduct large-scale clinical trials and gather comprehensive data, hindering the development of evidence-based treatment approaches. Moreover, the often late-stage diagnosis of intrahepatic cholangiocarcinoma presents a significant hurdle, as advanced disease is more difficult to treat effectively.

Additionally, the high cost of cutting-edge therapies, such as targeted treatments and immunotherapies, poses financial barriers to access for many patients and healthcare systems. These treatments may not be affordable or accessible to all, limiting their widespread adoption. Regulatory challenges, including the approval process for novel therapies, can also slow down the introduction of innovative treatments into the market. Furthermore, intrahepatic cholangiocarcinoma's heterogeneity at the molecular level presents a complex challenge. Tailoring treatments to each patient's specific genetic profile is promising but also demands advanced diagnostic capabilities and a deeper understanding of the disease's biology.

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

Key Intrahepatic Cholangiocarcinoma Companies

Virogin Biotech Ltd., Syndax Pharmaceuticals, Delcath Systems Inc., TriSalus Life Sciences, Inc., AstraZeneca, Relay Therapeutics, Inc., Kinnate Biopharma, Elucida Oncology, Lisata Therapeutics, Inc., Amgen, Jazz Pharmaceuticals, BeiGene, Ltd., and others

Key Intrahepatic Cholangiocarcinoma Therapies

VG161, SNDX-6352, Cisplatin and Gemcitabine, SD-101, Y-90 With Durvalumab/Gem/Cis, RLY-4008, KIN-3248, ELU001, LSTA1, Bemarituzumab, ZW25 (Zanidatamab), and others

Scope of the Intrahepatic Cholangiocarcinoma Market Report

  • Therapeutic Assessment: Intrahepatic Cholangiocarcinoma current marketed and emerging therapies
  • Intrahepatic Cholangiocarcinoma Market Dynamics: Conjoint Analysis of Emerging Intrahepatic Cholangiocarcinoma Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Intrahepatic Cholangiocarcinoma Market Access and Reimbursement

Discover more about intrahepatic cholangiocarcinoma drugs in development @ Intrahepatic Cholangiocarcinoma Clinical Trials

Table of Contents

1.

Intrahepatic Cholangiocarcinoma Market Key Insights

2.

Intrahepatic Cholangiocarcinoma Market Report Introduction

3.

Intrahepatic Cholangiocarcinoma Market Overview at a Glance

4.

Intrahepatic Cholangiocarcinoma Market Executive Summary

5.

Disease Background and Overview

6.

Intrahepatic Cholangiocarcinoma Treatment and Management

7.

Intrahepatic Cholangiocarcinoma Epidemiology and Patient Population

8.

Patient Journey

9.

Intrahepatic Cholangiocarcinoma Marketed Drugs

10.

Intrahepatic Cholangiocarcinoma Emerging Drugs

11.

Seven Major Intrahepatic Cholangiocarcinoma Market Analysis

12.

Intrahepatic Cholangiocarcinoma Market Outlook

13.

Potential of Current and Emerging Therapies

14.

KOL Views

15.

Unmet Needs

16.

SWOT Analysis

17.

Appendix

18.

DelveInsight Capabilities

19.

Disclaimer

20.

About DelveInsight

Related Reports

Intrahepatic Cholangiocarcinoma Pipeline

Intrahepatic Cholangiocarcinoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key intrahepatic cholangiocarcinoma companies, including Basilea Pharmaceutica, AstraZeneca, Delcath Systems Inc., Jiangsu HengRui Medicine Co., Ltd., Syndax Pharmaceuticals, Hutchison Medipharma Limited, Medivir, Newish Technology (Beijing) Co., Ltd., Relay Therapeutics, Inc., Exelixis, Forma Therapeutics, Inc., Xencor, Inc., Zymeworks, RedHill Biopharma Limited, Genoscience Pharma, Kinnate Biopharma, Taiho Oncology, Inc., Sirtex Medical, Virogin Biotech Ltd, TriSalus Life Sciences, Tyra Biosciences,  Siranomics, Instylla, Inc., among others.

Intrahepatic Cholangiocarcinoma Epidemiology

Intrahepatic Cholangiocarcinoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted intrahepatic cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Cholangiocarcinoma Market

Cholangiocarcinoma Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key cholangiocarcinoma companies, including AstraZeneca, Decalth Systems, Basilea Pharmaceutica, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, among others.

Cholangiocarcinoma Pipeline

Cholangiocarcinoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cholangiocarcinoma companies, including Merck KGaA, Eisai Inc., Janssen Research & Development, LLC, 3D Medicines, Basilea Pharmaceutica, Hutchison Medipharma Limited, Jiangsu HengRui Medicine, TransThera Sciences, RedHill Biopharma, Eli Lilly and Company, Elevation oncology, Senhwa Biosciences, InnoCare Pharma, Genoscience Pharma, Intensity therapeutics, Elucida Oncology, GlaxoSmithKline, Verismo Therapeutics, Sirnaomics, Toray Industries, Inc, Kinnate Biopharma, Boehringer Ingelheim, Wellmarker Bio, Arbele Limited, NGM Biopharmaceuticals, Inc., Elicio Therapeutics, Xencor, Inc., Celon Pharma SA, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com   
+1(919)321-6187
www.delveinsight.com   

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Modal title

Also from this source

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

Lewy body dementia (LBD) is a progressive neurological condition characterized by the accumulation of abnormal alpha-synuclein protein in the brain....

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

DelveInsight's Anti-GPC3 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.